Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7962594 | 0.88 | CYP1A2 (0.36) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL7972575 | 0.84 | MGLL (0.39) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL7976298 | 0.83 | ADRA1A (0.38) | ADRA1AADRA1BADRA1DHRH1 | |
| SCHEMBL7976303 | 0.83 | ADRA1A (0.38) | ADRA1AADRA1BADRA1DHRH1 | |
| SCHEMBL8173301 | 0.78 | MGLL (0.43) | MGLLCYP1A2CYP2D6FAAHALDH1A1 | |
| SCHEMBL7966161 | 0.78 | MGLL (0.43) | MGLLCYP1A2CYP2D6FAAHALDH1A1 | |
| SCHEMBL8174001 | 0.77 | ADRA1A (0.42) | MGLLCYP1A2CYP2D6FAAHADRA1A | |
| SCHEMBL5658840 | 0.77 | ADRA1A (0.42) | MGLLCYP1A2CYP2D6FAAHADRA1A | |
| SCHEMBL5662288 | 0.77 | ADRA1A (0.42) | MGLLCYP1A2CYP2D6FAAHADRA1A | |
| SCHEMBL7747876 | 0.74 | MGLL (0.39) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998285-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6255315-B1 | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-07-03 | — | — | US | disclosed |
| US-6228870-B1 | BENIGN PROSTATIC HYPERPLASIA; REDUCTION OF HYPOTENSION SIDE EFFECT | MERCK & CO., INC. | 2001-05-08 | — | — | US | disclosed |
| US-6143750-A | NITROGEN HETEROCYCLIC COMPOUNDS AS ENZYME INHIBITORS, FOR PROSTATE PROBLEMS AND MUSCLE RELAXANTS | MERCK & CO., INC. (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0998285-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-05-10 | — | — | EP | disclosed |
| US-6037354-A | ADMINISTERING PHENYL-SUBSTITUTED THIAZOLIDIN-4-ONE OR OXAZOLIDIN-2-ONE DERIVATIVE TO TREAT BENIGN PROSTATE HYPERPLASIA; SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1998057641-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-12-23 | — | — | WO | disclosed |